Interstitial Cystitis Clinical Trial
Official title:
Urinary Biomarkers Characteristic to Interstitial Cystitis- Proteomic Analysis of Urine
This is a retrospective study of urine samples stored in the Beaumont BioBank for future
research. The urine samples will be drawn from the urine back with patients previously
diagnosed with severe interstitial cystitis (IC), mild IC and no IC.
Interstitial Cystitis (IC) also known as Painful Bladder Syndrome (PBS) is a chronic
inflammatory disease. It has an unknown etiology, symptoms which present to varying degrees,
as well as an uncertain natural history. Diagnosis of IC is based on symptoms after
excluding more common and dangerous pathologies.
Extensive research has been done to understand the multifactorial etiology as well as to
help diagnose IC. Infectious, autoimmune and anatomic causes have been looked at with few
usable results. Inflammatory cells and markers have been more productive. Recently we have
shown in the rat model, that chemically induced inflammation, yields temporal increases in
measurable cytokines and chemokines in the urine. Moreover, this was done by Multiplex
analysis, using a multiple antigen bead assay (Luminex).
Cytokines and chemokines, part of an organisms proteome, allow for looking at the function
of a cell or organ at the time of the collection United States: Institutional Review Board.
Urine is obtained non-invasively and yields significant information about urinary tract
organs. The ability to find a biomarker or pattern of biomarker in the urine, diagnostic to
a disease, offers significant advantages over serum or tissue diagnosis.
We hope to identify patterns of inflammatory markers using proteomic analysis using the
previously mentioned multiple antigen cassettes (Luminex) as well as identify possible new
biomarkers using a Protein Chip SELDI--TOF (surface enhanced laser desorption
ionisation-time of flight) mass spectrometer. The detection of patterns or new biomarkers
has promise to help with diagnosis, treatment, and ultimately revealing the etiology and
course of IC.
;
Observational Model: Case Control, Time Perspective: Retrospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04313972 -
IC PaIN Trial: Interstitial Cystitis Pain Improvement With Naltrexone
|
Phase 4 | |
| Completed |
NCT03282318 -
A Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects With Bladder Pain Syndrome/Interstitial Cystitis
|
Phase 2 | |
| Completed |
NCT03463499 -
The Efficacy and Safety of Intravesical Hyaluronic Acid and Chondroitin Sulfate After Transurethral Resection of Hunner Lesion in Interstitial Cystitis/Bladder Pain Syndrome Patients
|
N/A | |
| Completed |
NCT02898220 -
Trans-MAPP II Study of Urologic Chronic Pelvin Pain
|
||
| Terminated |
NCT02591199 -
Engage 24: Evaluation of the Safety and Effectiveness of URG101 in Subjects With Interstitial Cystitis/Bladder Pain Syndrome
|
Phase 2 | |
| Completed |
NCT02247557 -
Intravesical Instillation of Liposome Encapsulated Botulinum Toxin A (Lipotoxin) in Treatment of Interstitial Cystitis
|
Phase 2 | |
| Active, not recruiting |
NCT01731470 -
Intravesical Liposomes for Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS)
|
N/A | |
| Completed |
NCT01197261 -
OXN PR vs Placebo in Opioid-naive Subjects Suffering From Severe Pain Due to Bladder Pain Syndrome (BPS)
|
Phase 2 | |
| Completed |
NCT00527917 -
A Pilot Clinical Investigation of the Efficacy and Safety of Uracyst® Versus Placebo in Patients With Interstitial Cystitis/Painful Bladder Syndrome.
|
Phase 2 | |
| Completed |
NCT00150488 -
URACYST® For the Treatment of GAG Deficient Interstitial Cystitis
|
N/A | |
| Recruiting |
NCT00094874 -
Acupuncture for the Treatment of Interstitial Cystitis (IC) Symptoms
|
Phase 3 | |
| Terminated |
NCT00086684 -
Effectiveness and Safety Study of Pentosan Polysulfate Sodium for the Treatment of Interstitial Cystitis
|
Phase 4 | |
| Recruiting |
NCT04845217 -
Peppermint Oil for the Treatment of Interstitial Cystitis / Bladder Pain Syndrome
|
Phase 1/Phase 2 | |
| Completed |
NCT04401176 -
Bladder Instillations Versus Onabotulinumtoxin A for Treatment of Interstitial Cystitis/Bladder Pain Syndrome
|
Phase 2 | |
| Recruiting |
NCT05147779 -
Safety of Cultured Allogeneic Adult Umbilical Cord Stem Cells for Peyronie's Disease, ED, and Interstitial Cystitis
|
Phase 1 | |
| Suspended |
NCT04450316 -
Low-dose Naltrexone for Bladder Pain Syndrome
|
Phase 2 | |
| Completed |
NCT04010513 -
Hypnosis for Bladder Pain Syndrome
|
N/A | |
| Completed |
NCT05179460 -
A Study of Pentosan Polysulfate Sodium and the Development of Pigmentary Maculopathy and Pigmentary Retinopathy
|
||
| Completed |
NCT02232282 -
Acupuncture for Female IC/PBSyndrome and Its Effect on the Urinary Microbiome: A Randomized Controlled Trial
|
N/A | |
| Completed |
NCT00546858 -
Relationship of Interstitial Cystitis to Vulvodynia
|
N/A |